
VTGN
Healthcare · Biotechnology · $8.0M market cap
$0.1805+0.00 (+1.0%)Nov 13, 4:27 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | -0.38 | -0.24 | +36.0% |
| Aug 14, 2026 | Before the open | -0.29 | -0.30 | -3.4% |
| Jun 15, 2026 | Time not confirmed | -0.42 | -0.37 | +11.9% |
| Feb 12, 2026 | After the close | -0.48 | -0.45 | +6.3% |
| Nov 13, 2025 | After the close | -0.44 | -0.54 | -22.7% |
| Aug 7, 2025 | After the close | -0.47 | -0.47 | 0.0% |
| Jun 17, 2025 | Time not confirmed | -0.85 | -0.44 | +48.2% |
| Feb 13, 2025 | After the close | -0.52 | -0.46 | +11.5% |
| Nov 7, 2024 | After the close | -0.39 | -0.42 | -7.7% |
| Aug 13, 2024 | After the close | -0.40 | -0.35 | +12.5% |
| Jun 11, 2024 | After the close | -0.36 | -0.25 | +30.6% |
| Feb 13, 2024 | After the close | -0.27 | -0.22 | +18.5% |
| Nov 9, 2023 | After the close | -0.68 |
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic…
| -0.66 |
| +2.9% |
| Aug 10, 2023 | After the close | -0.86 | -0.94 | -9.3% |
| Jun 28, 2023 | After the close | -1.50 | -1.75 | -16.7% |
| Feb 7, 2023 | After the close | -1.80 | -1.50 | +16.7% |
| Nov 10, 2022 | After the close | -0.60 | -2.40 | -300.0% |
| Aug 11, 2022 | After the close | -2.25 | -3.00 | -33.3% |
| Jun 23, 2022 | After the close | -0.06 | -0.09 | -50.0% |
| Feb 10, 2022 | After the close | -2.25 | -1.50 | +33.3% |
| Nov 10, 2021 | After the close | -2.25 | -2.10 | +6.7% |
| Aug 12, 2021 | After the close | -1.80 | -1.20 | +33.3% |
| Jun 29, 2021 | After the close | -0.05 | -0.20 | -300.0% |
| Feb 11, 2021 | After the close | -1.60 | -2.10 | -31.3% |
| Nov 12, 2020 | After the close | -0.70 | -1.50 | -114.3% |
| Aug 13, 2020 | After the close | -3.00 | -2.10 | +30.0% |
| Jun 29, 2020 | After the close | -0.08 | -0.07 | +12.5% |
| Feb 13, 2020 | After the close | -2.10 | -4.50 | -114.3% |
| Nov 7, 2019 | Before the open | -4.05 | -3.90 | +3.7% |
| Aug 13, 2019 | After the close | -3.30 | -4.50 | -36.4% |
| Jun 25, 2019 | After the close | -0.12 | -0.17 | -41.7% |
| Feb 12, 2019 | After the close | -6.45 | -7.20 | -11.6% |
| Oct 29, 2018 | After the close | -5.10 | -9.00 | -76.5% |
| Aug 14, 2018 | After the close | -4.20 | -6.00 | -42.9% |
| Jun 26, 2018 | After the close | -0.41 | -0.09 | +78.0% |
| Feb 12, 2018 | After the close | -8.10 | -7.50 | +7.4% |